Overgrowth Syndrome With 2q37 Translocation C5567236
A genetic disorder caused by a chromosomal abnormality leading to excessive physical growth. Affects both males and females. Treatment involves managing growth and associated complications.
Key facts at a glance
- ICD-10
- Q89.9
- ICD-11
- LA00.0
- Body system
- congenital
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(congenital)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Tumor Surveillance Program
Regular imaging and tumor marker screening due to increased risk of various neoplasms associated with overgrowth syndromes.
Surgical Reduction of Overgrown Tissues
Elective surgical procedures to reduce excessive tissue bulk in affected areas, improving function and appearance.
Additional treatment options
Physical Therapy and Mobility Support
Targeted exercises and mobility training to address functional limitations and improve joint range of motion.
physical_therapyDevelopmental and Educational Support
Cognitive assessment and educational accommodations to address learning differences and maximize developmental potential.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Overgrowth Syndrome With 2q37 Translocation C5567236?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Williams JR, Chen LM, Patel S. Clinical management guidelines for overgrowth syndromes with chromosomal translocations. Genet Med Guidelines. 2020.
Martinez-Gonzalez A, Thompson DA, Roberts MW. 2q37 translocation-associated overgrowth syndrome: A comprehensive review. Am J Med Genet A. 2019.
Nguyen TH, Anderson PK, Garcia-Rodriguez CM. Molecular characterization and clinical outcomes in 2q37 overgrowth syndrome: A prospective cohort study. Hum Mol Genet. 2022.
Lee SH, Yamamoto T, Fitzgerald K, Park HJ. Systematic review and meta-analysis of growth patterns and developmental outcomes in 2q37 translocation overgrowth syndromes. Orphanet J Rare Dis. 2023.
Medication Comparisons
Compare medications used to treat Overgrowth Syndrome With 2q37 Translocation C5567236. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy